At a glance
- Originator Aventis
- Class Radioprotectives
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Radioprotection
Most Recent Events
- 10 Oct 1996 No-Development-Reported for Radiation injuries/Radioprotection in USA (Unknown route)
- 02 May 1995 Preclinical development for Radiation injuries/Radioprotection in USA (Unknown route)